Influence of the α1-adrenergic antagonist, doxazosin, on noradrenaline-induced modulation of cytoskeletal proteins in cultured hyperplastic prostatic stromal cells

Prostate

Volumn 38, Issue 3, 1999, Pages 216-227

  Smith, Paul ^a   Rhodes, Nicholas P ^a   Ke, Youqiang ^a   Foster, Christopher S ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Doxazosin; Flow cytometry; Human prostate; Noradrenaline; Smooth muscle cells; Stroma; Tissue culture

Indexed keywords

ACTIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; CYTOSKELETON PROTEIN; DOXAZOSIN; FLUORESCEIN; MYOSIN; NORADRENALIN; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT;

ACTIN FILAMENT; ADRENERGIC STIMULATION; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOSKELETON; DRUG EFFECT; FLOW CYTOMETRY; FLUORESCENCE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; SMOOTH MUSCLE CONTRACTION; URINARY TRACT OBSTRUCTION; CELL CULTURE; CYTOLOGY; DRUG ANTAGONISM; MALE; METABOLISM; PHENOTYPE; SMOOTH MUSCLE; STROMA CELL;

ADRENERGIC ALPHA-ANTAGONISTS; CELL DIFFERENTIATION; CELLS, CULTURED; CYTOSKELETAL PROTEINS; DOXAZOSIN; HUMANS; MALE; MUSCLE, SMOOTH; NOREPINEPHRINE; PHENOTYPE; PROSTATIC HYPERPLASIA; RECEPTORS, ADRENERGIC, ALPHA-1; STROMAL CELLS;

EID: 0033556706     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19990215)38:3<216::AID-PROS6>3.0.CO;2-0     Document Type: Article

References (29)

1. Andersson KE, Lepor H, Wyllie H, Wyllie M. Prostatic alphal-adrenoceptors and uroselectivity. Prostate 1997;30:202-215.
2. Bartsch G, Müller HR, Oberholzer M, Rohr HP. Light microscopic analysis of the normal human prostate and of benign prostatic hyperplasia. J Urol 1979;122:487-491.
3. Deering RE, Bigler SA, King J, Choongkittaworn M, Aramburu E, Brawer MK. Morphometric quantitation of stroma in human benign prostatic hyperplasia. Urology 1994;44:64-70.
4. Marks LS, Treiger B, Dorey FJ, Fu YS, de Kernion JB. Morphometry of the prostate: I. Distribution of tissue components in hyperplastic glands. Urology 1994;44:486-492.
5. Shapiro E, Becich MJ, Hartanto V, Lepor H. The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic benign prostate hyperplasia. J Urol 1992;147:1293-1297.
6. Robert M, Costa P, Bressolle F, Mottet N, Navratil H. Percentage area density of epithelial and mesenchymal components in benign prostatic hyperplasia: comparison of results between single biopsy, multiple biopsies and multiple tissue specimens. Br J Urol 1995;75:317-324.
7. Shapiro E, Hartanto V, Lepor H. Quantifying the smooth muscle content of the prostate using double-immunoenzymatic staining and color assisted image analysis. J Urol 1992;147:1167-1170.
8. Chapple CR, Burt RP, Andersson PO, Greengrass P, Wyllie M, Marshall I. Alpha-1-adrenoceptor subtypes in the human prostate. Br J Urol 1994;74:585-589.
9. Lepor H, Tang R, Kobayashi S, Shapiro E, Forray C, Wetzel JM, Gluchowski C. Localization of the alpha 1A-adrenoceptor in the human prostate. J Urol 1995;154:2096-2099.
10. Marshall I, Burt RP, Chapple CR. Noradrenaline contractions of human prostate mediated by alpha 1A-(alpha 1c-) adrenoceptor subtype. Br J Pharmacol 1995;115:781-786.
11. Price DT, Schwinn DA, Lomasney JW, Allen LF, Caron MG, Lefkowitz RJ. Identification, quantification, and localization of mRNA for three distinct alpha 1 adrenergic receptor subtypes in human prostate. J Urol 1993;150:546-551.
12. Tseng-Crank J, Kost T, Goetz A, Hazum S, Robertson KM, Haizlip J, Godinot N, Robertson CN, Saussy D. The alpha 1c-adrenoceptor in human prostate: cloning, functional expression, and localization to specific prostatic cell types. Br J Pharmacol 1995;115:1475-1485.
13. Chapple CR. Selective alpha 1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience. Eur Urol 1996;29:129-144.
14. Hieble JP, Ruffolo RR. The use of alpha-adrenoceptor antagonists in the pharmacological management of benign prostatic hypertrophy: an overview. Pharmacol Res 1996;33:145-160.
15. Lepor H, Kaplan SA, Klimberg I, Mobley DF, Fawzy A, Gaffney M, Ice K, Dias N. Doxazosin for benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients. The Multicenter Study Group. J Urol 1997;157:525-530.
16. Pool JL. Doxazosin: a new approach to hypertension and benign prostatic hyperplasia. Br J Clin Pract 1996;50:154-163.
17. Smith P, Rhodes NP, Beesley C, Ke Y, Foster CS. Prostatic stromal cell phenotype is directly modulated by norepinephrine. Urology 1998;51:663-670.
18. Romijn JC, Verkoelen CF, Schroeder FH. Application of the MTT assay to human prostate cancer cell lines in vitro: establishment of test conditions and assessment of hormone-stimulated growth and drug-induced cytostatic and cytotoxic effects. Prostate 1988;12:99-110.
19. Campbell GR, Campbell JH. Smooth muscle phenotypic changes in arterial wall homeostasis: implications for the pathogenesis of atherosclerosis. Exp Mol Pathol 1985;42:139-162.
20. Thyberg J, Nilsson J, Palmberg L, Sjölund M. Adult human arterial smooth muscle cells in primary culture. Modulation from contractile to synthetic phenotype. Cell Tissue Res 1985;239:69-74.
21. Amark P, Kinn AC, Nergardh A. Receptor function studies in specimens from proximal human urethra obtained by transurethral resection. Urol Res 1992;20:55-58.
22. Bultmann R, Kurz AK, Starke K. Alpha 1-adrenoceptors and calcium sources in adrenergic neurogenic contractions of rat vas deferens. Br J Pharmacol 1994;111:151-158.
23. Chueh SC, Guh JH, Chen J, Lai MK, Ko FN, Teng CM. Inhibition by tamsulosin of tension responses of human hyperplastic prostate to electrical field stimulation. Eur J Pharmacol 1996;305:177-180.
24. Hatano A, Takahashi H, Tamaki M, Komeyama T, Koizumi T, Takeda M. Pharmacological evidence of distinct alpha 1-adrenoceptor subtypes mediating contraction of human prostatic urethra and peripheral artery. Br J Pharmacol 1994;113:723-728.
25. Kenny BA, Miller AM, Williamson IJ, O'Connell J, Chalmers DH, Naylor AM. Evaluation of the pharmacological selectivity profile of alpha 1-adrenoceptor antagonists at prostatic alpha 1-adrenoceptors: binding, functional and in vivo studies. Br J Pharmacol 1996;118:871-878.
26. Teng CM, Guh JH, Ko FN. Functional identification of alpha 1-adrenoceptor subtypes in human prostate: comparison with those in rat vas deferens and spleen. Eur J Pharmacol 1994;265: 61-66.
27. Tsujii T, Azuma H, Yamaguchi T, Oshima H. A possible role of decreased relaxation mediated by beta-adrenoceptors in bladder outlet obstruction by benign prostatic hyperplasia. Br J Pharmacol 1992;107:803-807.
28. Frick MH, Halttunen P, Himanen P, Huttunen M, Pörsti P, Pitkäjärvi T, Pöyhönen L, Pyykönen ML, Reinikainen P, Salmela P, Saraste M. A long-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate essential hypertension. Br J Clin Pharmacol 1986;21:55-62.
29. Peehl DM, Wehner N, Stamey TA. Activated Ki-ras oncogene in human prostatic adenocarcinoma. Prostate 1987;10:281-289.